Sight Sciences, Inc. (SGHT)

Nasdaq: SGHT · Surgical & Medical Instruments & Apparatus · Menlo Park, CA · filing with the SEC since 2011

Full chart Alerts Compare

Grade5.1

◀ Past 6.1● Present 4.6▶ Future 4.7

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Sight Sciences, Inc.

Nine metrics read from its own filings, by tense

Headline grade

5.1/10

◀ Past6.130% of the headline

● Present4.640% of the headline

▶ Future4.730% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.1/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.3/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 83rd percentile among 121 sector filers · read for itself

From the record

Sight Sciences, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

4.4/10

What has it actually done, year after year?

+22.9% a year over 6 filed years; profitable in 0 of 6.

weight 45% of this tense · 44th percentile among 105 sector filers · read for its customers

From the record

Sight Sciences, Inc.'s 6 filed years say what it did: revenue went from $28 million in fiscal 2020 to $77 million in fiscal 2025, up 22.9% a year; it rose in 3 of 5 years; the deepest fall was 5% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 6 of those years (its annual reports).

What it rests on

revenue growth over the filed span22.9%top 31% of its family
the share of years revenue rosebottom 23% of its family
the share of filed years with a profitbottom 23% of its family
the deepest fall from a revenue peak4.6%top 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

6.3/10

How has it treated the people who own it?

SI estimate 6.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 63rd percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 37% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Sight Sciences, Inc.'s shareholder treatment is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 37% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.6/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

5.6/10

Is it financially healthy right now?

ROE -60%: lost 60¢ per shareholder dollar. Leverage 45%: owes 45¢ per asset dollar.

weight 45% of this tense · 56th percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Sight Sciences, Inc. lost about 60 cents for every dollar of shareholders' money, and gross profitability: its products earned about 58 cents per dollar of everything the company owns. Leverage: it owed about 45 cents per dollar of assets, and net share issuance: its share count grew 4.0% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 47% of its family
return on equitybottom 41% of its family
gross profit against assetstop 24% of its family
the share count against the year beforetop 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.6/10

How strong is its position in its industry?

bottom 36% of 109 in its family; net margin -49.7%.

weight 33% of this tense · 36th percentile among 109 sector filers · read for its customers

From the record

Sight Sciences, Inc.'s standing among 109 graded names in its industry family: revenue of $77 million in fiscal 2025 ranks in the bottom 47% by size; a net margin of -49.7% ranks in the bottom 35%; revenue growth of 2.7% a year over the last 3 filed years ranks in the bottom 27% (its annual reports).

What it rests on

revenue against the family$77.4Mbottom 47% of its family
net margin-49.7%bottom 35% of its family
three-year revenue growth2.7%bottom 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

4.0/10

What are the people in charge doing?

bottom 40% of 91 in its family for leadership; chief executive since 2021.

weight 22% of this tense · 40th percentile among 91 sector filers · read for its shareholders

From the record

Sight Sciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Badawi, Paul (President and CEO, as filed), filing under that title since 2021-07-14, 5.3 years (top 47% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 3.7 years (bottom 20%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 46%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge8 in three years among 14 peoplebottom 46% of its family
the median years the people in charge have filed3.7 yearsbottom 20% of its family
the chief executive's years on the record5.3 yearstop 47% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.7/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

6.7/10

How much room does it have to grow?

top 33% of 104 in its family for room to expand.

weight 45% of this tense · 67th percentile among 104 sector filers · read for itself

From the record

Sight Sciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $92 million against debt of $40 million leaves 45% of its assets as net cash, top 19% of its family; cash from operations less capital spending is -38.7% of revenue (bottom 33%); a gross margin of 86.2% (top 4%); research spending of 18.9% of revenue (top 41%) (its annual report).

What it rests on

cash less debt against assets45.0%top 19% of its family
cash from operations less capital spending against revenue-38.7%bottom 33% of its family
gross margin86.2%top 4% of its family
research spending against revenue18.9%top 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

1.4/10

What could actually drive growth from here?

bottom 14% of 105 in its family for growth drivers.

weight 33% of this tense · 14th percentile among 105 sector filers · read for its customers

From the record

Sight Sciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.7% a year over the last three filed years against 22.9% over all 6, slowing (bottom 15% of its family); the newest year grew -3.1% (bottom 19%); research spending grew -13.9% a year (bottom 10%); capital spending grew -38.6% a year (bottom 11%) (its annual reports). Sight Sciences, Inc. reported 2 lines of business in fiscal 2025: Surgical Glaucoma at $76 million (98%), Dry Eye at $2 million (2%); 0 of 2 grew against the year before (its annual report).

What it rests on

three-year growth against the whole span-20.1 points a yearbottom 15% of its family
the newest year's revenue growth-3.1%bottom 19% of its family
three-year growth of research spending-13.9%bottom 10% of its family
three-year growth of capital spending-38.6%bottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.8/10

Did its newest year beat what its own record pointed to?

top 42% of 88 in its family for expectations against reality.

weight 22% of this tense · 58th percentile among 88 sector filers · read for its shareholders

From the record

Sight Sciences, Inc.'s newest year against its own record: revenue of $77 million in fiscal 2025 came in 8.5% below the $85 million its prior three years' pace pointed to (bottom 37% of its family); net income of $38 million against a prior three-year average of $64 million (top 38%); a net margin of -49.7% against -84.6% before (top 24%) (its annual reports).

What it rests on

revenue against the prior three years' pace-8.5%bottom 37% of its family
net income against the prior three years' average+40%top 38% of its family
net margin against its prior average+35.0 pointstop 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SGHT · research, not advice